(Q36925028)

17 August 2017

Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors (English)

1 reference

17 August 2017

Eschmann SM

1

1 reference

17 August 2017

Friedel G

2

1 reference

17 August 2017

Paulsen F

3

1 reference

17 August 2017

Reimold M

4

1 reference

17 August 2017

Hehr T

5

1 reference

17 August 2017

Scheiderbauer J

6

1 reference

17 August 2017

Budach W

7

1 reference

17 August 2017

Kotzerke J

8

1 reference

17 August 2017

Bares R

9

1 reference

17 August 2017

5 August 2006

1 reference

17 August 2017

6

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

17 August 2017

34

1 reference

17 August 2017

1

1 reference

17 August 2017

54-59

1 reference

The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562439

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

4 September 2018

1 reference

12 December 2020

Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer

1 reference

12 December 2020

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

1 reference

12 December 2020

Incidence of local recurrence and second primary tumors in resected stage I lung cancer

1 reference

12 December 2020

Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer

1 reference

12 December 2020

10.1007/S00259-006-0197-0

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

16896660

1 reference